Dr. Lal PathLabs (LALPATHLAB) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 10.7% year-over-year to INR 597 crore, with PAT up 19.3% to INR 98 crore, driven by strong Delhi NCR performance and expansion in Tier 2/3/4 and West/South India.

• Swasthfit bundled test packages grew 27.2% year-over-year, contributing 23% of revenue and patient volumes in Q3, with further growth expected in Q4.

• Investments in digital infrastructure, AI-driven diagnostics, and genomics (GeneEvolve, L-CORD) are enhancing service quality, efficiency, and expanding high-end test offerings.

• Focus remains on volume growth, network expansion, and maintaining quality, with no immediate plans for price increases despite industry trends.

• Approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2024.

Financial highlights

• Q3 FY25 consolidated revenue: INR 5,967 million (up from INR 5,389 million YoY); standalone revenue: INR 5,281 million (up from INR 4,760 million YoY).

• Q3 FY25 EBITDA: INR 154 crore (up 9.6% YoY), margin at 25.8%; PAT: INR 98 crore (up 19.3% YoY), PAT margin 16.4%.

• Q3 FY25 EPS: INR 11.6 (up from 9.8 YoY); YTD EPS: INR 39.9 (up 21.4% YoY).

• Net cash as of Dec 31, 2024: INR 1,123 crore; third interim dividend of INR 6/share, total YTD dividend INR 18/share.

• Other income increased to Rs. 25 crore in Q3 FY25 from Rs. 18 crore in Q3 FY24.

Outlook and guidance

• Targeting 15-20 new labs in FY25, with expansion focused on metro, Tier 1, and underserved Tier 3/4 markets.

• Patient volume growth YTD at 4.4%, with a goal to return to pre-COVID growth rates of 7-8% annually.

• CapEx guidance: INR 60-70 crore per year for maintenance, excluding major investments.

• Swasthfit contribution expected to peak in Q4 due to tax-related demand, with long-term growth aligned to NCD trends.

• Continued focus on innovation, bundled test packages, and high-end specialty tests to drive growth.